Genomic Health's Oncotype DX Test Meets Blue Cross and Blue Shield Standards | GenomeWeb
NEW YORK (GenomeWeb News) — A Blue Cross and Blue Shield Medical Advisory Panel has decided that Genomic Health’s Oncotype DX assay meets criteria set by the insurance company’s Technology Evaluation Center as a diagnostic for certain breast cancers, Genomic Health said today.
 
At a meeting last month the advisory panel concluded that the test meets its criteria for women with estrogen receptor-positive, node-negative, tamoxifen-treated breast cancer, Genomic Health said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.